ClinicalTrials.gg

Program

Atropine

Also written as “Atropine Sulfate”, “Low dose atropine sulfate eye drops” and “atropine sulfate”.

Its studies are mostly in Myopia · Myopia, Degenerative · Insulin Resistance · Rhinitis, Allergic, Seasonal, led by 14 companies.

Furthest: phase 3, since Sep 27, 201817 company-led studies, 6 open or runningNext primary completion: Sep 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hai Yen Eye Care20 open or runningphase 1since Sep 27, 2018Sep 27, 2018none ahead
Laboratorios Sophia S.A de C.V.20 open or runningphase 1since Mar 23, 2022Mar 23, 2022none ahead
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical22 open or runningphase 3since Jan 5, 2024Jan 5, 2024none ahead
cloudbreak-therapeutics-llc10 open or runningphase 2since May 5, 2021May 5, 2021none ahead
Eyenovia10 open or runningphase 3since May 7, 2019May 7, 2019none ahead
IDB VisionCare SDN BHD11 open or runningphase 3since Sep 16, 2025Sep 16, 2025Sep 2027phase 3 · NCT07329777
Kubota Pharmaceutical11 open or runningno phasesince Aug 26, 2023Aug 26, 2023none ahead
magna-pharmaceuticals-inc10 open or runningphase 2since Feb 26, 2014Feb 26, 2014none ahead
microdose-defense-products-l-l-c10 open or runningphase 1since Jul 22, 2009Jul 22, 2009none ahead
Ocumension Therapeutics (Suzhou)10 open or runningphase 3since Nov 18, 2024Nov 18, 2024none ahead
Ocus Innovation Ireland11 open or runningphase 3since May 23, 2025May 23, 2025Dec 31, 2027phase 3 · NCT07028827
scimar-ltd10 open or runningno phasesince Oct 29, 2020Oct 29, 2020none ahead
Sydnexis10 open or runningphase 3since Apr 12, 2019Apr 12, 2019none ahead
Zhaoke (Hong Kong) Ophthalmology Pharmaceutical11 open or runningphase 1since Apr 23, 2023Apr 23, 2023none ahead
  • Named in jiangsu hengrui medicine’s own pipeline as Atropine eye drops, phase 4, as of Jul 31, 2026 (source).

Also a collaborator on its studies: euromed-pharma-services-srl, novotech-australia-pty-limited, source-nutraceutical-inc and brien-holden-vision.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Jul 22, 2009.

  1. Sep 27, 2018Hai Yen Eye Care's first study: phase 1 study in MyopiaNew to Hai Yen Eye CareHai Yen Eye Care · NCT03690414 · 52 enrolled · Vietnam
  2. Oct 5, 2018Phase 1 study in MyopiaHai Yen Eye Care · NCT03699423 · 58 enrolled · Vietnam
  3. Apr 12, 2019Sydnexis's first study: phase 3 study in MyopiaNew to SydnexisSydnexis · NCT03918915 · 852 enrolled · United States, Austria, Slovakia
  4. May 7, 2019Eyenovia's first study: phase 3 study in MyopiaNew to EyenoviaEyenovia · NCT03942419 · 438 enrolled · United States
  5. Oct 29, 2020scimar-ltd's first study: no phase study in Insulin ResistanceNew to scimar-ltdscimar-ltd · NCT04625088 · 24 enrolled · Canada
  6. May 5, 2021cloudbreak-therapeutics-llc's first study: phase 2 study in Myopia, DegenerativeNew to cloudbreak-therapeutics-llccloudbreak-therapeutics-llc · NCT05372991 · 84 enrolled · Australia
  7. Mar 23, 2022Laboratorios Sophia S.A de C.V.'s first study: phase 1 study in MyopiaNew to Laboratorios Sophia S.A de C.V.Laboratorios Sophia S.A de C.V. · NCT05470881 · 29 enrolled · Mexico
  8. Jul 28, 2022Phase 1 study in MyopiaLaboratorios Sophia S.A de C.V. · NCT05481489
  9. Apr 23, 2023Zhaoke (Hong Kong) Ophthalmology Pharmaceutical's first study: phase 1 study in PharmacokineticsNew to Zhaoke (Hong Kong) Ophthalmology PharmaceuticalZhaoke (Hong Kong) Ophthalmology Pharmaceutical · NCT05855018 · 30 planned · China
  10. Aug 26, 2023Kubota Pharmaceutical's first study: no phase study in MyopiaNew to Kubota PharmaceuticalKubota Pharmaceutical · NCT06034379 · 45 planned · Taiwan
  11. Jan 5, 2024Zhaoke (Guangzhou) Ophthalmology Pharmaceutical's first studies: 2 phase 3 studies in MyopiaNew to Zhaoke (Guangzhou) Ophthalmology PharmaceuticalZhaoke (Guangzhou) Ophthalmology Pharmaceutical · NCT06209281, NCT06209320
  12. Nov 18, 2024Ocumension Therapeutics (Suzhou)'s first study: phase 3 study in MyopiaNew to Ocumension Therapeutics (Suzhou)Ocumension Therapeutics (Suzhou) · NCT06697522 · 148 enrolled · China
  13. May 23, 2025Ocus Innovation Ireland's first study: phase 3 study in MyopiaNew to Ocus Innovation IrelandOcus Innovation Ireland · NCT07028827 · 234 planned · Albania, Italy, Poland and more
  14. Sep 16, 2025IDB VisionCare SDN BHD's first study: phase 3 study in Myopia ProgressionNew to IDB VisionCare SDN BHDIDB VisionCare SDN BHD · NCT07329777 · 144 planned · Malaysia

Ahead

  1. Sep 2027Primary completion: phase 3 study in Myopia ProgressionIDB VisionCare SDN BHD · NCT07329777
  2. Dec 31, 2027Primary completion: phase 3 study in MyopiaOcus Innovation Ireland · NCT07028827

TargetBeta

“Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M1 antagonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
GlycopyrrolateruleNovartisphase 487

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07329777Myopia Progression · Malaysia3RecruitingIDB VisionCare SDN BHDSep 2027144
NCT07028827Myopia · Albania, Italy, Poland and more3RecruitingOcus Innovation IrelandDec 31, 2027234
NCT06697522Myopia · China3CompletedOcumension Therapeutics (Suzhou)Oct 6, 2023148
NCT06209320Myopia · China3Active, not recruitingZhaoke (Guangzhou) Ophthalmology PharmaceuticalMar 21, 2025777
NCT06209281Myopia · China3Active, not recruitingZhaoke (Guangzhou) Ophthalmology PharmaceuticalAug 20, 2023526
NCT06034379Myopia · Taiwan–RecruitingKubota PharmaceuticalDec 202545
NCT05855018Pharmacokinetics · China1RecruitingZhaoke (Hong Kong) Ophthalmology PharmaceuticalJun 202330
NCT05481489Myopia1WithdrawnLaboratorios Sophia S.A de C.V.Mar 31, 20230
NCT05470881Myopia · Mexico1CompletedLaboratorios Sophia S.A de C.V.Dec 26, 202229
NCT05372991Myopia, Degenerative · Australia2Completedcloudbreak-therapeutics-llcJan 18, 202384
NCT04625088Insulin Resistance · Canada–Completedscimar-ltdAug 6, 202124
NCT03942419Myopia · United States3TerminatedEyenoviaOct 31, 2024438
NCT03918915Myopia · United States, Austria, Slovakia3CompletedSydnexisMay 2, 2024852
NCT03699423Myopia · Vietnam1CompletedHai Yen Eye CareApr 30, 201858
NCT03690414Myopia · Vietnam1CompletedHai Yen Eye CareFeb 2, 201952
NCT02082054Rhinitis, Allergic, Seasonal · United States2UNKNOWNmagna-pharmaceuticals-incMay 2014125
NCT00947596Organophosphate Poisoning · United States1Completedmicrodose-defense-products-l-l-cJul 201018

How it is read

Names in the registry

  • “Atropine Sulfate”, 3 entries
  • “Low dose atropine sulfate eye drops”, 3 entries
  • “atropine sulfate”, 2 entries
  • “SYD-101 0.01%”, 1 entry
  • “SYD-101 0.03%”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.